28 May 2026VideosAmericasPhil Hamzik, Wolf Greenfield | Adam Gastonguay, Regeneron | Paul Fleming, Seaport Therapeutics | Robin Weatherhead, Ventus Therapeutics | Erica LoRe, Invivyd
WATCH: Strategic protection for life sciences innovations in a changing landscape—trade secrets vs patents
Phil Hamzik, Shareholder at Wolf Greenfield, leads a panel discussion with Adam Gastonguay, Director and Patent Counsel at Regeneron; Paul Fleming, Senior Director of Intellectual Property at Seaport Therapeutics; Robin Weatherhead, Vice President of Intellectual Property and Legal at Ventus Therapeutics; and Erica LoRe, Senior Director and Intellectual Property Counsel at Invivyd.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.